Clinical evidence demonstrates MammaPrint and our genomic tumor sub-typing test, BluePrint, can help answer many clinical treatment questions in early-stage invasive breast cancer. Results may help inform whether chemotherapy is likely to provide benefit and who may be able to avoid chemotherapy. Treatment decisions should be made collaboratively between a patient and their physician. Results should be taken in the context of other relevant clinico-pathological factors and standard practice of medicine.